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Summary We evaluated the myelotoxicity and the anti-tumor potential of tallimustine, three of its analogues and carzelesin, with melphalan
as reference substance. Tallimustine was tested by clonogenic assays on both human bone marrow (BM) and cord blood (hCB) cells, the
other compounds on hCB only. The degree of inhibition of the haemopoietic progenitors GM-CFC, CFC-E and BFU-E was evaluated after
exposure to different concentrations. The same schedules were tested on five tumour cell lines. We found that the dose-response curves for
tallimustine on BM and hCB cells were similar. Carzelesin was shown to be the most potent of the substances tested and to be the one with
the best in vitro therapeutic index; of the distamycin analogues, the one bearing an alpha-bromoacrylic group (FCE 25450) had the best
index. For melphalan, tallimustine and carzelesin, the concentration inhibiting the growth of 70% of progenitor cells in vitro (ID70) was similar
to the concentrations found in the serum of patients treated at the maximum tolerated dose (MTD). We conclude that hCB cells may be used
instead of BM cells for in vitro myelotoxicity tests. Therapeutic indexes can be extrapolated from this model and could help in selecting the
most promising analogue for further clinical development. The in vitro-active concentrations are similar to myelotoxic concentrations in
patients, suggesting a predictive value for the assay.
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Phase I clinical trials remainpivotal in thedevelopment ofnew anti-
cancer drugs, but more refined methods are needed to minimize the
number ofpatients treated with inactive dosages. Traditionally, the
starting dose for phase I studies corresponds to one-tenth of the
mouse LD10, with subsequent dose escalations according to a modi-
fied Fibonacci scheme, however methods to reduce the number of
dose levels have been proposed in recent years. One of them, the
'pharmacologically guided dose escalation' method, relies on the
observation that for many (but not all) drugs plasma levels in mice
at the LDIO are similar to those found in humans at the MTD, and
that similar AUC values in mice and humans will produce similar
toxic effects (Davis et al, 1988; Collins et al, 1990; Gianni et al,
1990). Nevertheless, because of interspecies variations in schedule
dependency, tissue distribution and steepness of the slope of the
toxicity vs concentration curve, the planning and performance of
phase I trials cannot be based on animal experiments only, but
should also be based on in vitro data on human tissues (EORTC
Pharmacokinetics and Metabolism Group, 1987). The toxicity of
new substances against human haemopoietic tissue has been
assessed in clonogenic tests on bone marrow cells after exposure to
the drug under study. A number of agents were tested by this
method, which proved to predict myelotoxicity reliably for many
substances (Du et al, 1990, 1991). These tests can also predict the
rate of increase in myelotoxicity during dose escalation as well as
the interpatient variability (Parchment et al, 1993).
We decided to use a similar type of test to study DNA minor
groove alkylators, a family ofdrugs forwhich phase MI/I evaluations
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have recently been started. These drugs appear to display a high
DNA sequence specificity of alkylation (Broggini et al, 1991;
D'Incalci, 1994), which in turn could lead to a higher specificity of
HCI
CI .
Tallimustine
HCI
Br N HCI
N
N
N HCI
ci \-N eN
N
>=\I
FCE25450
FCE28102
FCE281 64
Figure 1 Chemical structure of the distamycin derivatives used
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the anti-tumour effect. Members ofthis family are carzelesin, which
is a CC-1065 derivative, and the distamycin derivatives, some of
which have been shown to possess anti-tumour activity in several
models (Pezzoni et al, 1991; Li et al, 1992; D'Alessio et al, 1994).
In order to compare the in vitro activity of these substances, we
determined their cytotoxicity in tumour cell lines and their toxic
effects on human haemopoietic tissue. The latter are usually studied
on human bone marrow cells, but these are difficult to obtain in
large amounts. Given the similarity between bone marrow (BM)
and human cord blood-derived haematopoietic cells (Hows et al,
1992), we developed a model based on cord blood (hCB) cells and
used it, after validation, to compare the myelotoxicity ofcarzelesin
and offourdistamycin derivatives.
MATERIALS AND METHODS
Cytotoxic treatment of haemopoietic cells
The distamycin derivatives tallimustine (FCE24517), FCE25450,
FCE28164 and FCE28102 (Figure 1) were provided by Pharmacia
(Milan, Italy), and carzelesin was a gift from Upjohn (Kalamazoo,
MI, USA). The classical alkylating agent melphalan was used as a
reference compound. All drugs were provided as dry powder and
were reconstituted with dimethylsulphoxide (DMSO) (distamycin
analogues), hydrochloric acid (L-PAM) orN,N,dimethylacetamide
(carzelesin) and diluted with medium. To avoid degradation ofthe
drugs, all solutions were prepared freshly before each experiment.
The actual concentration of the solutions was verified by light
absorption on a standard densitometer.
BM cells wereobtainedby aspiration oftheposterioriliac crests of
seven normal volunteers (aged 32-45). hCB was obtained from
placentas after vaginal deliveries. Cells from 14 hCB samples were
used. In all cases, the samples were collected in sterile, heparin-
containing tubes, stored at4°C andprocessed within48 h. Cells were
separated by density centrifugation on a Ficoll gradient to obtain
mononuclear cells (MNCs), which were then adherent cell depleted
by overnight incubation in 20% fetal calf serum (FCS) in Iscove's
modified Dulbecco medium (IMDM) in plastic flasks. Aliquoted
cells were cryopreserved at-80°C in 10% DMSO until use.
After thawing, cells were exposed for 1 h to the drug to be tested
at 37'C in IMDM. Cells were then washed twice with medium
before being plated on clonogenic assays. The experiments with
tallimustine were performed on both BM and hCB, and the other
drugs were tested on hCB cells only. Tallimustine was also tested in
continuous exposure, by plating BM cells with different concentra-
tions ofthe drug, which then remained in the medium forthe subse-
quent 2 weeks. For each drug, a first set of3-6 experiments was set
up at concentrations ranging overfour logs, while in a second set of
3-6 experiments doses were chosen within the ID30-ID 9 range to
fine tune the dose-response curve at the critical concentrations.
Clonogenic assays
Clonogenic assays were performed according to previously
described methods (Coutinho et al, 1993). Briefly, cells were
plated in methylcellulose and IMDM, supplemented with 30%
FCS, 1% bovine serum albumin (BSA), 10% conditioned medium
from the bladdercarcinoma cell line 5637 and 2 IU ofrecombinant
erythropoietin. Triplicate cultures were prepared with a final
concentration of 1 or 2 x 105 MNC ml in 4-well tissue culture
plates (Falcon). The plates were incubated for 14 days at 37°C in
5% carbon dioxide and fully humidified air. Colonies were scored
on an inverted microscope at 7 days (GM-CFCd7 and CFU-E) and
at 14 days (GM-CFCdl4, BFU-E and Mix-CFC) according to
established criteria: GM-CFC contain at least 50 cells, while a
CFC-E is a group ofat least five haemoglobinized cells. BFU-E are
composed of at least three clusters of haemoglobinized cells near
to each other. Mix-CFC are colonies containing both myeloid and
erythroid components (Coutinho et al, 1993; Lewis et al, 1994).
Cell line experiments
Monolayer cultures of human colon adenocarcinoma LoVo
(Drewinko et al, 1976) and HT-29 (Fogh and Trempe, 1975) were
maintained in Ham's F12 medium supplemented with 1% vitamins
(Vitamins BME solution), 2mM L-glutamine and 10% FCS. The
human lymphoblastic leukaemia cell line CEM (Beck et al, 1979;
Danks et al, 1987) was maintained in minimal essential medium
(MEM) supplemented with 10% inactivated FCS and 1% vitamin,
and the chronic myeloid leukaemia EM-2 (Keating, 1987) and T-
cell leukaemia Jurkatt (Weiss et al 1985) human cell lines were
grown in RPMI supplemented with 10% FCS, 2 mM L-glutamine,
penicillin and streptomycin.
The drug concentrations required for 70% cell growth inhibition
(IC70) were determined for LoVo and HT-29 cells using a single-
cell plating technique. Exponentially growing cells were seeded
48 h before treatment and then exposed to drugs for 1 h. The
medium was removed and cells were incubated in drug-free
medium. The number of adherent colonies (at least 50 cells) was
determined by manual counting on a light microscope after 8-10
days of incubation at 37°C in 5% carbon dioxide. In vitro drug
sensitivity against EM2, Jurkatt and CEM cells was evaluated by
counting surviving cells. Exponentially growing cells were seeded
in test tubes (lx105 cells ml-1, 2 ml per tube) in the presence of
various concentrations ofdrug. The incubation mixture was kept at
37°C for 1 h, and cells were then washed and incubated for48 h in
drug-free medium. The inhibition ofcell growth was evaluated by
counting surviving cells with a Coulter counter.
The antiproliferative activity of the drugs was calculated from
dose-response curves and expressed as IC70 (dose causing the
inhibition of cell growth in treated cultures relative to untreated
controls).
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Figure 2 Dose-response curve of hCB cells on GM-CFCd14 exposed for 1 h
to tallimustine. Median of seven experiments (-) and range (. . .). ID70,
concentration at which 30% of colonies survive
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Figure 3 Dose-response curve of BM and hCB cells on GM-CFCd14
exposed for 1 h to tallimustine. Median of seven experiments on hCB (-)
and of seven experiments on BM (. . .). Error bars represent range values
Table 1 Median ID70 and range (ng ml-') of minor groove alkylators and L-
PAM on hCB cells after 1 h exposure
GM-CFCd7 GM-CFCd14 CFC-E BFU-E
Tallimustine 145 165 180 220
(n = 8) (90-225) (110-235) (90-250) (175-310)
FCE25450 410 630 390 460
(n = 8) (370-540) (420-810) (330-460) (410-690)
FCE28102 2600 7700 2200 4600
(n = 6) (800-4500) (3200-9300) (800-4500) (1900-8700)
FCE28164 310 420 570 790
(n= 7) (100-470) (190-470) (150-700) (610-870)
Carzelesin 1.9a 3.6a 2.2 1.9
(n= 11) (1.7-5) (2.2-6.3) (<1-3.6) (1.2-4.7)
L-PAM 640a 1420a 600b 860b
(n = 6) (590-760) (1040-2010) (260-780) (620-980)
aGM-CFC d7 vs GM-CFC d14, P<0.05. bCFCE vs BFU-E, P<0.05.
Table 2 Rate of increase in myelotoxicity of distamycin derivatives,
carzelesin and L-PAM (1 h exposure)
GM-CFCd7 GM-CFCdl4 CFC-E BFU-E
Tallimustine 30 38 25 52
FCE25450 47 43 120 57
FCE28102 15 11 21 10
FCE28164 12 48 26 50
Carzelesin 40 30 13 48
L-PAM 20 27 36 80
Analysis of data and statistics
Dose-response curves were produced by computer using a stan-
dard software program (Excel version 5.0). The concentration
inhibiting the growth of70% ofCFC (ID70) was extrapolated from
the curves (Figure 2), and the ID70 on GM-CFC d14 was taken as
an index of myelotoxicity. For each drug and progenitor type, the
slope of the dose-response curve was also calculated. This para-
meter, which others have called 'rate ofincrease in myelotoxicity'
(Parchment et al, 1993), was determined by measuring the
percentage increase in cell inhibition when doubling the drug dose
in the interval between ID30 and ID80, a dose range which included
the linear part of the curve for all substances. The ratio of the
average IC70 ofthe drugs against five tumourcell lines was used as
an anti-tumour index. An 'in vitro therapeutic index' could then be
calculated by dividing the myelotoxicity index (ID70) by the anti-
tumour index (IC70).
For each drug, the analysis ofdifferences in the cell inhibition of
the various progenitor cells was performed using parametric and
non-parametric one-way analysis ofvariance. Whenever a statisti-
cally significant result for the global F-test was detected, multiple
pairwise comparisons were performed. The adjustments of P-
values for multiple comparisons were obtained using the Bootstrap
regression model (Friedman, 1981).
RESULTS
Initial studies were performed on BM cells to evaluate the concen-
tration-cytotoxicity curve of 1 h exposure to tallimustine in a
range of drug concentrations between 100 and 400 ng ml-'.
Linearity was observed in the range between 20 and 200 ng ml-'
(Figure 3). Subsequent experiments were set up with tallimustine
on both BM and hCB cells at doses ranging from 20 to 200 ng
ml-', constituting the linear part of the curve. Figure 3 shows a
comparison between the toxicity oftallimustine (1 h exposure) for
BM and hCB cells on GM-CFCdl4. Even though a remarkable
variability was observed, similar sensitivity to the drug was
observed for both cell sources, the median ID70 for GM-CFCdl4
being 135 ng ml-' (range 105-240 ng ml-') for BM and 165 ng ml-'
(110-235 ng ml-') for hCB.
We then tested, on hCB only, the effect of 1 h exposure to the
three other distamycin derivatives, carzelesin and L-PAM. Cell
inhibition was determined for all progenitors assessable by this
assay, i.e. GM-CFCd7 andd14, CFU-E, BFU-E and CFU-mix. For
all the types ofcells, the ID70 was calculated, except for CFU-mix,
which were found in low numbers (even in controls) and hence did
not allow any analysis. Table 1 reports the median ID70 of each
drug against any progenitor type. Overall, all drugs appear to be
more toxic against more differentiated progenitors (CFCd7) than
against more immature progenitors (CFCdl4). The differences
observed, however, were not statistically significant, with the
exception of carzelesin and L-PAM. Carzelesin was the most
potent drug. Tallimustine was the most potent among distamycin
analogues, while L-PAM had an intermediate potency between
FCE25450 and FCE28102.
The cytotoxicity ofdifferent exposure times was studied only for
tallimustine. The ID70 for GM-CFCd7 from hCB was 130 ng ml-'
(range 110-240 ng ml-') for 1 h exposure and 13 ng ml' (4-28 ng
ml-') for continuous exposure; for GM-CFCdl4, the corresponding
figures were 135 ng ml-' (range 105-240 ng ml-') and 16 ng ml-'
(2-32 ngml-')respectively. It appears that, forthis drug, continuous
exposure is approximately ten times more myelotoxic than a 1-h
exposure, suggesting that the myelotoxicity is schedule dependent.
Table 2 reports the rate of increase in myelotoxicity for each
drug and cell type. For GM-CFCdl4, tallimustine, FCE28164 and
FCE25450 showed the highest rate of increase, corresponding to
the steepest curve. FCE28102 had the lower rate of increase. This
order did not apply to the other precursors.
The cytotoxic activity of a 1-h treatment with distamycin deriv-
atives, carzelesin and L-PAM against five tumour cell lines is
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Table 3 Cytotoxicity of minor groove alkylators and L-PAM on tumour cell lines: IC70 ± s.e. (ng ml-') after 1 h exposure
Compound EM 2 Jurkatt CEM HT-29 LoVo Mean
Tallimustine 152 ±25 49± 11 47± 9 328± 75 245± 33 165
FCE25450 157 ±26 48± 15 95± 22 624± 24 97± 4 204
FCE28102 1891 ±293 319 ± 67 1770 ± 116 16096±2081 3958±585 4807
FCE28164 312± 11 50± 12 69± 12 712± 103 376± 39 304
L-PAM 2770 95 1763 ±48 1287 ± 341 9020±765 5023± 177 3954
Carzelesin 0.079 0.01 0.016 ± 0.001 0.26± 0.01 0.64± 0.02 0.16± 0.015 0.23
EM2, human chronic myeloid leukaemia; Jurkatt, human T-cell leukaemia; CEM, human lymphoblastic leukaemia; HT-29 and LoVo, human colon
adenocarcinoma.
Table 4 Myelotoxic and anti-tumour effect of drugs
L-PAM Tallimustine FCE25450 FCE28102 FCE28164 Carzelesin
Myelotoxic dose 1420 165 630 7700 420 3.6
(ID70 on GM-CFC d14 from hCB)
Cytotoxic dose 3954 165 204 4807 304 0.23
(IC70 on cancer cell lines)
In vitro therapeutic index 0.4 1 3.1 1.6 1.4 16
In vitro therapeutic index: ID70 on hCB/IC70 on cancer cell lines.
reported in Table 3. Acute leukaemia cell lines were the most
sensitive, while the response ofthe other cell lines was more vari-
able. Table 4 reports the in vitro therapeutic index ofeach drug. It
appears that carzelesin, the most potent compound, has the best in
vitro therapeutic index. In fact, the dose of carzelesin that is toxic
against tumour cell lines is approximately 16 times lower than the
one that is toxic against human haematopoietic cells or, in other
words, the cytotoxic dose is 16 times lower than the myelotoxic
one. For the other compounds, differences between cytotoxic and
myelotoxic doses are not so strikingly different.
DISCUSSION
To gain more insight into the characteristics ofminor groove alky-
lators and to optimize the planning of phase I trials with these
drugs, we performed myelotoxicity experiments on human
haematopoietic tissue, using cord blood as a source of cells. The
advantages of this cell source for pharmacological testing are that
they are easily obtained and available in abundance. Haema-
topoietic stem and precursor cells are normally present in fetal
blood and were shown to share many features with BM cells
(Hows et al, 1992), although some immunophenotypic and in vitro
growth characteristics are not completely superimposable (Hao et
al, 1995; Fritsch et al, 1996). Recently, Leglise et al (1996) demon-
strated the equivalence of both stem cell sources for in vitro
myelotoxicity tests for several classes of drugs, including anti-
cancer, antibiotic and antiviral drugs.
Experiments performed in our laboratory with doxorubicin and
other anthracyclines produced very similar results on hCB and on
BM (manuscript in preparation). The equivalence of BM and hCB
for pharmacology tests is also supported by our results with
tallimustine, showing similar median ID70 for the two sources, i.e.
135 ng ml-' (range 105-240 ng ml-') and 165 ng ml (range
110-235 ng ml-') respectively. In addition, the ID70 we obtained
with L-PAM for GM-CFC and BFU-E on hCB cells were similar to
those reported by other groups on BM cells (Du et al, 1990). Our
results are not in agreement with those of Volpe et al (1992), who
tested tallimustine on BM cells; in their hands, tallimustine was
shown to be more toxic than in ours, and erythroid cells appeared
to be more sensitive than myeloidprogenitors. These discrepancies
might not be related to the cell source but to technical differences,
such as mode of drug dilution, time of exposure (4 h instead of 1
h), smaller number of experiments and different range of concen-
trations tested. We have observed an important variability of ID70
on all the progenitors tested because cells from some sources are
intrinsically more sensitive to drugs than others. This corresponds
to the difference in chemotherapy tolerance seen among patients in
the clinic, the cause ofwhich is still mostly unknown, even though
differences in intracellular distribution, active cell excretion and
integrity ofrepair mechanisms can be speculated.
To ensure clinically relevant information, we studied the
dose-response curve in the range ofclinically relevant concentra-
tions (ID30-ID80). For tallimustine, for example, the ID30 is around
100 ng mll and the ID90 is around 300 ng ml-', so that the testing
ofconcentrations much below or above this range would not yield
much information. The estimation of the toxic drug levels could
become very helpful in the setting of pharmacologically guided
dose escalation, whereby the goal would become the attainment of
plasma concentrations similar to those achieved in animals at toxic
doses and within the range ofthose found to be cytotoxic in clono-
genic tests (Du et al, 1995). The drug concentrations defined in our
experiments are in agreement with those achieved in humans: the
ID70 range found for tallimustine against myeloid progenitors
(90-235 ng ml-') is in the range (104-189 ng ml') of those
reported in four patients 1 h after administration ofdoses near the
MTD (Sessa et al, 1994). A similar trend was also seen for carze-
lesin (in vitro 1.7-6.3 ng ml-', in humans 1-2 ng ml-') (Wolff et
al, 1996) and L-PAM (in vitro 590-2100 ng ml-', in humans
100-800 ng ml-' at a dose below the MTD) (Zucchetti et al,
1988). A similar in vivo-in vitro correlation for myelotoxicity
between concentrations active on clonogenic tests and plasma
concentrations achieved in phase I studies was found with other
compounds such as pyrazolacridine (Parchment et al, 1994;
Rowinsky et al, 1995).
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Clonogenic tests could also help to define which component of
the drug exposure (peak, AUC, time above a threshold concentra-
tion) is the most important for toxicity. For tallimustine, all prog-
enitors were killed when exposed in vitro for 1 h at 400 ng ml-' or
higher. Based on our data showing that a continuous exposure of
40 ng ml-' is as toxic as 400 ng m1- for 1 h, we believe that AUC
and not the time above a critical concentration is the main determi-
nant oftoxicity.
The pattern of toxicity of a drug on haemopoietic cells in vitro
could be useful for predicting the pattern of myelotoxicity in
humans. In the process of blood cell differentiation, a common
stem cell capable ofautoreplication gives rise to a lymphatic and a
myeloid precursor. The latter, which corresponds in vitro to the
long-term culture-initiating cell (LTC-IC), generates progenitor
cells of granulocytes and macrophages (GM-CFCdl4), erythro-
cytes (BFU-E) and megakaryocytes (BFU-Meg), which are clono-
genic and hence recognizable in vitro. These progenitors then
differentiate into the final mature blood elements through an inter-
mediate step ofcells (Lewis et al, 1994) which are still clonogenic
(GM-CFCd7, CFC-E and Meg-CFC). Our assay can test myeloid
and erythroid clonogenic cells, while the analysis of LTC-IC
requires more sophisticated and time-consuming methods based
on the long-term culture principle (Hows et al, 1992). The study of
megakaryocyte progenitors would also be relevant for the clinic,
but this technique is still insufficiently standardized to be applied.
From our results, we could predict that tallimustine and
FCE28102 (which seemed to be more toxic against the myeloid
than the erythroid line) would induce, mainly, a selective granulo-
cytopenia, while L-PAM, carzelesin and the other distamycin
derivatives would mainly affect the erythroid line. Preliminary
clinical data with tallimustine and carzelesin support this hypoth-
esis. Even though anaemia is clinically less relevant and more
difficult to evaluate than leucopenia, the difference in the toxic
effects on the myeloid and erythroid lines is theoretically inter-
esting as it illustrates how changes in the chemical structure ofthe
alkylating moiety can affect the response ofeach cell type.
It should be pointed out that the mechanism of cytotoxicity of
minor groove binders has still not been fully elucidated. The
compounds that have been investigated in greater detail are CC-
1065 or its analogues, including carzelesin and the distamycin
derivative tallimustine. CC-1065 and its analogues alkylate
adenine N3 with a high selectivity for adenine located in the
sequence AAAAA or PUNAAA, whereas tallimustine alkylates
adenine N3 located in the hexamer TTTTGA. Therefore, even
though all these compounds can be classified as DNA minor
groove alkylators, it appears that they can hit different DNA
sequences, possibly causing function impairment of different
genes. Recent studies have in fact shown that both the CC-1065
type of compounds and distamycin derivatives can selectively
block the sequence-specific binding of transcription factors, thus
impairing the transcription of genes regulated by these proteins. It
is then conceivable that different minor groove binders possess
different sequence preferences for DNA binding, thereby causing
different biological effects, either in terms of their anti-tumour
activity or of their toxicity. This could be an explanation for the
difference in the pattern of myelotoxicity of tallimustine and
carzelesine and of tallimustine and some of the other distamycin
derivatives, such as FCE 25450.
For all drugs tested, the less differentiated precursors (GM-
CFCdl4 and BFU-E) seemed to be less affected than the more
mature ones (GM-CFCd7 and CFC-E). The higher resistance to
cytostatics could be interpreted as a higher capability of immature
cells to repair DNA or, alternatively, be attributed to the smaller
proportion ofimmature cells that are in a proliferative state.
We can hypothesize that similar resistance mechanisms could
play a role in the different patterns ofmyelotoxicity in humans, for
example tallimustine was shown to cause an early, brief and selec-
tive granulocytopenia (Sessa et al, 1994) while carzelesin induced
a delayed, long-lasting and cumulative pancytopenia (Wolff et al,
1996). For tallimustine, we can hypothesize that early precursor
cells (i.e. LTC-IC) might be more resistant while clonogenic cells
such as GM-CFC are very sensitive to the drug; for carzelesin, the
contrary might be true. These issues could be elucidated by the
long-term culture system, which could help to define the differen-
tiation step of the haematopoietic process that is most affected by
the exposure to a given cytotoxic agent.
Minor-groove alkylators remain a promising field of research.
Other distamycin analogues could now enter phase I trials, and
data from our clonogenic tests will be useful for selecting the
compounds most promising for clinical development. From the
results ofthis study, it appears that the analogue with the best ther-
apeutic index (three times better than tallimustine, approximately
nine times better than L-PAM) is the distamycin derivative
FCE25450, which bears an a-bromoacrylic group, and its further
development in phase I trials should be encouraged. On the other
hand, the excellent in vitro therapeutic index of carzelesin has not
yet been confirmed in clinical studies, whereby delayed, long-
lasting and cumulative myelosuppression represents the dose-
limiting toxicity.
In conclusion, we have shown that valuable predictive informa-
tion on the myelotoxicity of cytotoxic agents can be obtained by
clonogenic assays on human cord blood cells. By comparing new
analogues to known drugs, a therapeutic index as well as the
starting dose and the magnitude of dose escalations for clinical
studies could be suggested.
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